Affinity Asset Advisors, LLC Vincerx Pharma, Inc. Transaction History

Affinity Asset Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.0 - $1.72 $0 - $204,117	118,673 Added 8.64%	1,492,771 $2.06 Million
Q1 2022 May 13, 2022	BUY	$0.0 - $0.0 $0 - $0	238,733 Added 21.03%	1,374,098 $5.5 Million
Q4 2021 Feb 11, 2022	BUY	$0.0 - $0.0 $0 - $0	130,365 Added 12.97%	1,135,365 $11.6 Million
Q3 2021 Nov 12, 2021	BUY	$0.0 - $0.0 $0 - $0	166,689 Added 19.88%	1,005,000 $16.3 Million
Q2 2021 Aug 13, 2021	BUY	$0.0 - $27.0 $0 - $7.97 Million	295,301 Added 54.38%	838,311 $10.9 Million
Q1 2021 May 14, 2021	BUY	$22.6 - $31.0 $3.16 Million - $4.34 Million	140,010 Added 34.74%	543,010 $10.5 Million
Q4 2020 Feb 12, 2021	BUY	$12.85 - $19.95 $5.18 Million - $8.04 Million	403,000 New	403,000 $8.43 Million

11M

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $6.57M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.